Abstract
Many patients with pulmonary sarcoidosis experience reduced quality of life. Although oral corticosteroids are the most common agents used in sarcoidosis, very little is known on the effects on quality of life. In this double-blind, placebo-controlled trial, newly diagnosed patients without an indication for high dose immunosuppressive therapy were randomised to once-daily dexamethasone 1mg (6.5mg prednisone equivalent) or placebo for 6 months. The primary study parameter was the subscale physical functioning of the 36-item Short Form health survey (SF-36). Secondary parameters included five other patient reported outcome measures, disease activity markers and plasma cytokine profiles. A total of 16 patients was randomised to dexamethasone (n=7) and placebo (n=9). During follow-up no significant difference for physical functioning was measured (p=0.18). Dexamethasone treated patients showed a decrease in fatigue score (Checklist Individual Strength) from 106 (baseline) to 88 (3 months; p=0.03); 86 (6 months; p=0.05); 79 (9 months; p=0.04); 90 (12 months; p=0.03). Placebo treated patients showed no change: 96 (baseline) to 105 (3 months; p=0.16); 91 (6 months; p=0.48); 92 (9 months; p=0.61); 95 (12 months; p=0.90). During treatment with dexamethasone significant improvements in the SF-36 subscales vitality and pain, and a significant reduction in serum angiotensin-converting enzyme, soluble interleukin 2 receptor levels and serum cytokines and chemokines were measured. Low-dose dexamethasone results in a reduction of the inflammatory profile and has the potential to improve quality of life parameters and fatigue.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have